Review



mab against human cd16  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Miltenyi Biotec mab against human cd16
    Mab Against Human Cd16, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 108 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+against+human+cd16/CD16+Antibody%2C+anti-human/bio_rxiv__64898__2026__03__30__715436-171-222-231
    Average 95 stars, based on 108 article reviews
    mab against human cd16 - by Bioz Stars, 2026-10
    95/100 stars

    Images

    Related Articles

    other:

    Article Title: DNAM-1 immunoreceptor integrates innate and adaptive immune programs to drive intestinal inflammation
    Article Snippet: Anti-TNF-α mAb (XT3.11) was purchased from Selleck (Houston, USA). mAbs against mouse CD49b (DX5), CD11b (M1/70), CD86 (GL1), CD155 (3F1), rat IgG2a, rat IgG1, hamster IgG1, hamster IgG2 (KKLH), rat IgG2a (RTK2758), Ly-6G (1A8), CD40 (3/23), CD112 (829038), Gr-1 (RB6-8C5), CD90.2 (53-2.1), CD11c (HL3), CD11b (M1/70), Ly-6C (AL-21), NKp46 (29A1.4), RORγt (Q31-378), IFN-γ (XMG1.2), IL-17A (TC11-18H10), IL-12(p40/p70) (C11.5), human CD19 (HIB19), CD138 (MI15), CD117 (104D2) and Fluorochrome-conjugated streptavidin were purchased from BD Biosciences (Franklin Lakes, NJ). mAb against T1/ST2 (DJ8) was purchased from MD Bioproducts (St. Paul, MN). mAb against mouse IL-22 (1H8PWSR), CD25 (7D4),T-bet (4B10) GATA-3 (TWAL), HIF-1 alpha (Mgc3), and IL-22 (IL22JOP), and human CD127 (eBioRDR5) was purchased from Invitrogen (Waltham, MA). mAbs against mouse TCR-β (H57-597), CD11b (M1/70), CD155 (TX56), KLRG1 (2F1), CD25 (PC61), NKp46 (29A1.4), Ly-6G (IA8), Gr-1 (RB6-8C5), CD80 (B7-1), CD103 (2E7), CD49b (DX5), CD45RB (C363-16A), CD90.2 (53-2.1), I-A/I-E (M5/114.15.2), CD45.2 (104), CD45 (30-F11), CD64 (X54-5/7.1), CD170/Siglec-F (S17007L), CD11c (N418), CD4 (RMA-5), CD4 (GK1.5), F4/80 (BM8), CD127(A7R34), CD11b (M1/70), Ly-6C (HK1.4), CCR6 (29-2L17), T-bet (4B10), IFN-γ (XMG1.2), GM-CSF (MP1-22E9), human CD161 (HP-3G10), CCR6 (G034E3), NKp44 (P44-8), CRTH2 (BM16), and Fluorochrome-conjugated streptavidin were purchased from Biolegend (San Diego, CA). mAb against phospho-Akt(T308) (D25E6) and phospho-S6 ribosomal protein (s235/236) (D57.2.2E) were purchased from Cell Signaling Technology (Massachusetts, USA). mAb against human CD3 was purchased from Cytec Biosciences (California, USA). mAb against human CD16 and FcεRIα were purchased from Miltenyi biotec.



    Similar Products

    mab against human cd16  (Miltenyi Biotec)
    95
    Miltenyi Biotec mab against human cd16
    Mab Against Human Cd16, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+against+human+cd16/CD16+Antibody%2C+anti-human/bio_rxiv__64898__2026__03__30__715436-171-222-231
    Average 95 stars, based on 1 article reviews
    mab against human cd16 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    fitc-conjugated mouse mab against human cd16 3g8, igg 1  (Becton Dickinson)
    90
    Becton Dickinson fitc-conjugated mouse mab against human cd16 3g8, igg 1
    Fitc Conjugated Mouse Mab Against Human Cd16 3g8, Igg 1, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+against+human+cd16/anti+cd56/pmc08093814-82-14-25
    Average 90 stars, based on 1 article reviews
    fitc-conjugated mouse mab against human cd16 3g8, igg 1 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    mouse mab against human cd16 b73.1  (Thermo Fisher)
    90
    Thermo Fisher mouse mab against human cd16 b73.1
    Role of CD32a and mCD14 in LTF-IC-mediated monocyte activation. Human monocytes were stimulated with 30 μg/ml huLTF-M860-IC ( A ), or RA-IgG-IC ( B ), in the presence or absence ( Med ) of blocking mAbs (15 μg/ml) against <t>CD16</t> (B73.1, eBioscience), or CD32 (IV.3, eBioscience), or CD64 (10.1, Stem Cell Tech) for 18 h, followed by quantitation of TNF-α in the culture supernatant by ELISA. ( C ) Monocytes stimulated with 3 μg/ml LPS in the presence or absence ( Med ) of anti-CD32a mAb (15 μg/ml), or isotype control Abs as controls. ( D ) Human monocytes were stained with 30 μg/ml M860-IC containing FITC-conjugated huLTF in the presence or absence ( M860-IC ) of 10 μg/ml soluble recombinant human CD14 ( M860-IC + sCD14 ) or OVA ( M860-IC + OVA ) for 1 h at 4 °C, followed by FACS analysis. Unstained cells were included as negative control (filled histogram). ( E ) Human monocytes were treated with 30 μg/ml huLTF-M860 IC in the presence of mouse mAbs (15 μg/ml) against human LRP-1 (α LRP1 ), nucleolin-1 (α Nucleolin ), or CD14 (α CD14 ) for 18 h, followed by quantitation of TNF-α levels in the culture supernatants by ELISA. Cells treated with 1 μg/ml PMA in the presence of αCD14 mAb or isotype control mAb were included for specificity controls. ( F ) The anti-CD14 mAb was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays with mouse IgG1 (1 μg/ml) as isotype control. Readings from unstimulated cells ( Med ) are also indicated in the figure. ( G ) TLR4-specific inhibitor CLI-095 was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays monitoring TNF-α production. Monocytes stimulated with 5 μg/ml zymosan in the presence or absence of 1 μg/ml CLI-095 were included as specificity control. For ELISAs, values are mean TNF-α concentration (ng/ml) ± SEM from triplicate cultures. * p < 0.05, ** p < 0.01 compared with M860-IC- or LPS-stimulated cells in the presence of isotype control Abs or in the absence of inhibiting agents. NS : not statistically significant. Results are representative of three independent experiments.
    Mouse Mab Against Human Cd16 B73.1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+against+human+cd16/anti+mouse+cd16+32/pmc05484712-179-0-11
    Average 90 stars, based on 1 article reviews
    mouse mab against human cd16 b73.1 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    monoclonal antibodies (mabs) against human cd19, cd16, cd56, cd8, cd14  (ImmunoTools)
    90
    ImmunoTools monoclonal antibodies (mabs) against human cd19, cd16, cd56, cd8, cd14
    Role of CD32a and mCD14 in LTF-IC-mediated monocyte activation. Human monocytes were stimulated with 30 μg/ml huLTF-M860-IC ( A ), or RA-IgG-IC ( B ), in the presence or absence ( Med ) of blocking mAbs (15 μg/ml) against <t>CD16</t> (B73.1, eBioscience), or CD32 (IV.3, eBioscience), or CD64 (10.1, Stem Cell Tech) for 18 h, followed by quantitation of TNF-α in the culture supernatant by ELISA. ( C ) Monocytes stimulated with 3 μg/ml LPS in the presence or absence ( Med ) of anti-CD32a mAb (15 μg/ml), or isotype control Abs as controls. ( D ) Human monocytes were stained with 30 μg/ml M860-IC containing FITC-conjugated huLTF in the presence or absence ( M860-IC ) of 10 μg/ml soluble recombinant human CD14 ( M860-IC + sCD14 ) or OVA ( M860-IC + OVA ) for 1 h at 4 °C, followed by FACS analysis. Unstained cells were included as negative control (filled histogram). ( E ) Human monocytes were treated with 30 μg/ml huLTF-M860 IC in the presence of mouse mAbs (15 μg/ml) against human LRP-1 (α LRP1 ), nucleolin-1 (α Nucleolin ), or CD14 (α CD14 ) for 18 h, followed by quantitation of TNF-α levels in the culture supernatants by ELISA. Cells treated with 1 μg/ml PMA in the presence of αCD14 mAb or isotype control mAb were included for specificity controls. ( F ) The anti-CD14 mAb was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays with mouse IgG1 (1 μg/ml) as isotype control. Readings from unstimulated cells ( Med ) are also indicated in the figure. ( G ) TLR4-specific inhibitor CLI-095 was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays monitoring TNF-α production. Monocytes stimulated with 5 μg/ml zymosan in the presence or absence of 1 μg/ml CLI-095 were included as specificity control. For ELISAs, values are mean TNF-α concentration (ng/ml) ± SEM from triplicate cultures. * p < 0.05, ** p < 0.01 compared with M860-IC- or LPS-stimulated cells in the presence of isotype control Abs or in the absence of inhibiting agents. NS : not statistically significant. Results are representative of three independent experiments.
    Monoclonal Antibodies (Mabs) Against Human Cd19, Cd16, Cd56, Cd8, Cd14, supplied by ImmunoTools, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+against+human+cd16/anti+cd16/10__1128_slash_aac__03559___14-54-37-38
    Average 90 stars, based on 1 article reviews
    monoclonal antibodies (mabs) against human cd19, cd16, cd56, cd8, cd14 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    mouse mab against human cd14, cd16, cd56, cd19  (Thermo Fisher)
    90
    Thermo Fisher mouse mab against human cd14, cd16, cd56, cd19
    Role of CD32a and mCD14 in LTF-IC-mediated monocyte activation. Human monocytes were stimulated with 30 μg/ml huLTF-M860-IC ( A ), or RA-IgG-IC ( B ), in the presence or absence ( Med ) of blocking mAbs (15 μg/ml) against <t>CD16</t> (B73.1, eBioscience), or CD32 (IV.3, eBioscience), or CD64 (10.1, Stem Cell Tech) for 18 h, followed by quantitation of TNF-α in the culture supernatant by ELISA. ( C ) Monocytes stimulated with 3 μg/ml LPS in the presence or absence ( Med ) of anti-CD32a mAb (15 μg/ml), or isotype control Abs as controls. ( D ) Human monocytes were stained with 30 μg/ml M860-IC containing FITC-conjugated huLTF in the presence or absence ( M860-IC ) of 10 μg/ml soluble recombinant human CD14 ( M860-IC + sCD14 ) or OVA ( M860-IC + OVA ) for 1 h at 4 °C, followed by FACS analysis. Unstained cells were included as negative control (filled histogram). ( E ) Human monocytes were treated with 30 μg/ml huLTF-M860 IC in the presence of mouse mAbs (15 μg/ml) against human LRP-1 (α LRP1 ), nucleolin-1 (α Nucleolin ), or CD14 (α CD14 ) for 18 h, followed by quantitation of TNF-α levels in the culture supernatants by ELISA. Cells treated with 1 μg/ml PMA in the presence of αCD14 mAb or isotype control mAb were included for specificity controls. ( F ) The anti-CD14 mAb was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays with mouse IgG1 (1 μg/ml) as isotype control. Readings from unstimulated cells ( Med ) are also indicated in the figure. ( G ) TLR4-specific inhibitor CLI-095 was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays monitoring TNF-α production. Monocytes stimulated with 5 μg/ml zymosan in the presence or absence of 1 μg/ml CLI-095 were included as specificity control. For ELISAs, values are mean TNF-α concentration (ng/ml) ± SEM from triplicate cultures. * p < 0.05, ** p < 0.01 compared with M860-IC- or LPS-stimulated cells in the presence of isotype control Abs or in the absence of inhibiting agents. NS : not statistically significant. Results are representative of three independent experiments.
    Mouse Mab Against Human Cd14, Cd16, Cd56, Cd19, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+against+human+cd16/pmc00385405-468-17-29
    Average 90 stars, based on 1 article reviews
    mouse mab against human cd14, cd16, cd56, cd19 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    fitc-conjugated murine monoclonal antibodies (mabs) against human cd34, cd3, cd19, cd20, cd56, cd11b, cd14, cd16, cd38  (Becton Dickinson)
    90
    Becton Dickinson fitc-conjugated murine monoclonal antibodies (mabs) against human cd34, cd3, cd19, cd20, cd56, cd11b, cd14, cd16, cd38
    Role of CD32a and mCD14 in LTF-IC-mediated monocyte activation. Human monocytes were stimulated with 30 μg/ml huLTF-M860-IC ( A ), or RA-IgG-IC ( B ), in the presence or absence ( Med ) of blocking mAbs (15 μg/ml) against <t>CD16</t> (B73.1, eBioscience), or CD32 (IV.3, eBioscience), or CD64 (10.1, Stem Cell Tech) for 18 h, followed by quantitation of TNF-α in the culture supernatant by ELISA. ( C ) Monocytes stimulated with 3 μg/ml LPS in the presence or absence ( Med ) of anti-CD32a mAb (15 μg/ml), or isotype control Abs as controls. ( D ) Human monocytes were stained with 30 μg/ml M860-IC containing FITC-conjugated huLTF in the presence or absence ( M860-IC ) of 10 μg/ml soluble recombinant human CD14 ( M860-IC + sCD14 ) or OVA ( M860-IC + OVA ) for 1 h at 4 °C, followed by FACS analysis. Unstained cells were included as negative control (filled histogram). ( E ) Human monocytes were treated with 30 μg/ml huLTF-M860 IC in the presence of mouse mAbs (15 μg/ml) against human LRP-1 (α LRP1 ), nucleolin-1 (α Nucleolin ), or CD14 (α CD14 ) for 18 h, followed by quantitation of TNF-α levels in the culture supernatants by ELISA. Cells treated with 1 μg/ml PMA in the presence of αCD14 mAb or isotype control mAb were included for specificity controls. ( F ) The anti-CD14 mAb was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays with mouse IgG1 (1 μg/ml) as isotype control. Readings from unstimulated cells ( Med ) are also indicated in the figure. ( G ) TLR4-specific inhibitor CLI-095 was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays monitoring TNF-α production. Monocytes stimulated with 5 μg/ml zymosan in the presence or absence of 1 μg/ml CLI-095 were included as specificity control. For ELISAs, values are mean TNF-α concentration (ng/ml) ± SEM from triplicate cultures. * p < 0.05, ** p < 0.01 compared with M860-IC- or LPS-stimulated cells in the presence of isotype control Abs or in the absence of inhibiting agents. NS : not statistically significant. Results are representative of three independent experiments.
    Fitc Conjugated Murine Monoclonal Antibodies (Mabs) Against Human Cd34, Cd3, Cd19, Cd20, Cd56, Cd11b, Cd14, Cd16, Cd38, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+against+human+cd16/anti+cd34/pm11841418-52-57-58
    Average 90 stars, based on 1 article reviews
    fitc-conjugated murine monoclonal antibodies (mabs) against human cd34, cd3, cd19, cd20, cd56, cd11b, cd14, cd16, cd38 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    mab against cd16  (Miltenyi Biotec)
    94
    Miltenyi Biotec mab against cd16
    Role of CD32a and mCD14 in LTF-IC-mediated monocyte activation. Human monocytes were stimulated with 30 μg/ml huLTF-M860-IC ( A ), or RA-IgG-IC ( B ), in the presence or absence ( Med ) of blocking mAbs (15 μg/ml) against <t>CD16</t> (B73.1, eBioscience), or CD32 (IV.3, eBioscience), or CD64 (10.1, Stem Cell Tech) for 18 h, followed by quantitation of TNF-α in the culture supernatant by ELISA. ( C ) Monocytes stimulated with 3 μg/ml LPS in the presence or absence ( Med ) of anti-CD32a mAb (15 μg/ml), or isotype control Abs as controls. ( D ) Human monocytes were stained with 30 μg/ml M860-IC containing FITC-conjugated huLTF in the presence or absence ( M860-IC ) of 10 μg/ml soluble recombinant human CD14 ( M860-IC + sCD14 ) or OVA ( M860-IC + OVA ) for 1 h at 4 °C, followed by FACS analysis. Unstained cells were included as negative control (filled histogram). ( E ) Human monocytes were treated with 30 μg/ml huLTF-M860 IC in the presence of mouse mAbs (15 μg/ml) against human LRP-1 (α LRP1 ), nucleolin-1 (α Nucleolin ), or CD14 (α CD14 ) for 18 h, followed by quantitation of TNF-α levels in the culture supernatants by ELISA. Cells treated with 1 μg/ml PMA in the presence of αCD14 mAb or isotype control mAb were included for specificity controls. ( F ) The anti-CD14 mAb was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays with mouse IgG1 (1 μg/ml) as isotype control. Readings from unstimulated cells ( Med ) are also indicated in the figure. ( G ) TLR4-specific inhibitor CLI-095 was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays monitoring TNF-α production. Monocytes stimulated with 5 μg/ml zymosan in the presence or absence of 1 μg/ml CLI-095 were included as specificity control. For ELISAs, values are mean TNF-α concentration (ng/ml) ± SEM from triplicate cultures. * p < 0.05, ** p < 0.01 compared with M860-IC- or LPS-stimulated cells in the presence of isotype control Abs or in the absence of inhibiting agents. NS : not statistically significant. Results are representative of three independent experiments.
    Mab Against Cd16, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+against+human+cd16/CD16+Antibody%2C+anti-human%2C+pure%2C+REAfinity/pm11087410-128-31-34
    Average 94 stars, based on 1 article reviews
    mab against cd16 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Role of CD32a and mCD14 in LTF-IC-mediated monocyte activation. Human monocytes were stimulated with 30 μg/ml huLTF-M860-IC ( A ), or RA-IgG-IC ( B ), in the presence or absence ( Med ) of blocking mAbs (15 μg/ml) against CD16 (B73.1, eBioscience), or CD32 (IV.3, eBioscience), or CD64 (10.1, Stem Cell Tech) for 18 h, followed by quantitation of TNF-α in the culture supernatant by ELISA. ( C ) Monocytes stimulated with 3 μg/ml LPS in the presence or absence ( Med ) of anti-CD32a mAb (15 μg/ml), or isotype control Abs as controls. ( D ) Human monocytes were stained with 30 μg/ml M860-IC containing FITC-conjugated huLTF in the presence or absence ( M860-IC ) of 10 μg/ml soluble recombinant human CD14 ( M860-IC + sCD14 ) or OVA ( M860-IC + OVA ) for 1 h at 4 °C, followed by FACS analysis. Unstained cells were included as negative control (filled histogram). ( E ) Human monocytes were treated with 30 μg/ml huLTF-M860 IC in the presence of mouse mAbs (15 μg/ml) against human LRP-1 (α LRP1 ), nucleolin-1 (α Nucleolin ), or CD14 (α CD14 ) for 18 h, followed by quantitation of TNF-α levels in the culture supernatants by ELISA. Cells treated with 1 μg/ml PMA in the presence of αCD14 mAb or isotype control mAb were included for specificity controls. ( F ) The anti-CD14 mAb was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays with mouse IgG1 (1 μg/ml) as isotype control. Readings from unstimulated cells ( Med ) are also indicated in the figure. ( G ) TLR4-specific inhibitor CLI-095 was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays monitoring TNF-α production. Monocytes stimulated with 5 μg/ml zymosan in the presence or absence of 1 μg/ml CLI-095 were included as specificity control. For ELISAs, values are mean TNF-α concentration (ng/ml) ± SEM from triplicate cultures. * p < 0.05, ** p < 0.01 compared with M860-IC- or LPS-stimulated cells in the presence of isotype control Abs or in the absence of inhibiting agents. NS : not statistically significant. Results are representative of three independent experiments.

    Journal: Scientific Reports

    Article Title: Extraordinarily potent proinflammatory properties of lactoferrin-containing immunocomplexes against human monocytes and macrophages

    doi: 10.1038/s41598-017-04275-7

    Figure Lengend Snippet: Role of CD32a and mCD14 in LTF-IC-mediated monocyte activation. Human monocytes were stimulated with 30 μg/ml huLTF-M860-IC ( A ), or RA-IgG-IC ( B ), in the presence or absence ( Med ) of blocking mAbs (15 μg/ml) against CD16 (B73.1, eBioscience), or CD32 (IV.3, eBioscience), or CD64 (10.1, Stem Cell Tech) for 18 h, followed by quantitation of TNF-α in the culture supernatant by ELISA. ( C ) Monocytes stimulated with 3 μg/ml LPS in the presence or absence ( Med ) of anti-CD32a mAb (15 μg/ml), or isotype control Abs as controls. ( D ) Human monocytes were stained with 30 μg/ml M860-IC containing FITC-conjugated huLTF in the presence or absence ( M860-IC ) of 10 μg/ml soluble recombinant human CD14 ( M860-IC + sCD14 ) or OVA ( M860-IC + OVA ) for 1 h at 4 °C, followed by FACS analysis. Unstained cells were included as negative control (filled histogram). ( E ) Human monocytes were treated with 30 μg/ml huLTF-M860 IC in the presence of mouse mAbs (15 μg/ml) against human LRP-1 (α LRP1 ), nucleolin-1 (α Nucleolin ), or CD14 (α CD14 ) for 18 h, followed by quantitation of TNF-α levels in the culture supernatants by ELISA. Cells treated with 1 μg/ml PMA in the presence of αCD14 mAb or isotype control mAb were included for specificity controls. ( F ) The anti-CD14 mAb was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays with mouse IgG1 (1 μg/ml) as isotype control. Readings from unstimulated cells ( Med ) are also indicated in the figure. ( G ) TLR4-specific inhibitor CLI-095 was titrated against LTF-M860 IC (30 μg/ml) in monocyte activation assays monitoring TNF-α production. Monocytes stimulated with 5 μg/ml zymosan in the presence or absence of 1 μg/ml CLI-095 were included as specificity control. For ELISAs, values are mean TNF-α concentration (ng/ml) ± SEM from triplicate cultures. * p < 0.05, ** p < 0.01 compared with M860-IC- or LPS-stimulated cells in the presence of isotype control Abs or in the absence of inhibiting agents. NS : not statistically significant. Results are representative of three independent experiments.

    Article Snippet: Mouse mAbs against human CD16 (B73.1) or CD64 (10.1) were from eBioscience.

    Techniques: Activation Assay, Blocking Assay, Quantitation Assay, Enzyme-linked Immunosorbent Assay, Control, Staining, Recombinant, Negative Control, Concentration Assay